Mediclinic International plc Holding(s) in Company (8389B)
June 14 2021 - 10:30AM
UK Regulatory
TIDMMDC
RNS Number : 8389B
Mediclinic International plc
14 June 2021
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(" Mediclinic ", the " Company ", or the " Group ")
14 June 2021
TR-1: S tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the MEDICLINIC INTERNATIONAL PLC
underlying issuer of existing shares
to which voting rights are attached:
--------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify):
----
3. Details of person subject to the notification obligation
Name PUBLIC INVESTMENT CORPORATION SOC
LIMITED
City and country of registered office PRETORIA, SOUTH AFRICA
(if applicable)
4. Full name of shareholder(s) (if different from 3.)
Name
--------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------
5. Date on which the threshold was 11/06/2021
crossed or reached:
--------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 14/06/2021
--------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 9.992% 9.992% 737 243 810
------------------ --------------------- -------------- --------------------
Position of
previous notification
(if
applicable) 10.108% 10.108%
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) Directive
(DTR5.1) (DTR5.2.1) 2004/109/EC)
(DTR5.2.1)
----------------------------
73 665 137 9.992%
----------------------- ---------------------------- ------------------------- ---------------
SUBTOTAL 8. A 73 665 137 9.992%
----------------------------------------------------- ------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion Period rights that may rights
be acquired if
the instrument
is
exercised/converted.
------------- ------------------------------- -------------------------------- ---------------
SUBTOTAL 8. B 1 NIL NIL
------------------------------- -------------------------------- ---------------
B 2: Financial Instruments with similar economic effect according to Art.
13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date Conversion cash voting rights rights
instrument Period settlement
------------------ -------------------- --------------------- --------------------
SUBTOTAL 8.B.2 NIL NIL
--------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer
Full chain of controlled undertakings through which the voting rights X
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional
rows as necessary)
Name % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is higher
is higher than the instruments if it than the notifiable
notifiable threshold equals or is higher threshold
than the notifiable
threshold
---------------------- --------------------- --------------------------
PUBLIC INVESTMENT
CORPORATION SOC
LIMITED 9.992% 9.992%
---------------------- --------------------- --------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
-------------------------------------------------
The number and % of voting rights N/A
held
-------------------------------------------------
The date until which the voting rights N/A
will be held
-------------------------------------------------
11. Additional information
Name: REITUMETSE KAU
E-Mail: Reitumetse.Kau@pic.gov.za
TEL: 0127423747
Place of completion PRETORIA, SOUTH AFRICA
Date of completion 14 June 2021
-----------------------
About Mediclinic International plc
Mediclinic is a diversified international private healthcare
services group, established in South Africa in 1983, with divisions
in Switzerland, Southern Africa (South Africa and Namibia) and the
UAE.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
At 31 March 2021, Mediclinic comprised 72 hospitals, eight
sub-acute and specialised hospitals, 18 day case clinics and 18
outpatient clinics. Hirslanden operated 17 hospitals and four day
case clinics in Switzerland with more than 1 900 inpatient beds;
Mediclinic Southern Africa operations included 48 hospitals (three
of which in Namibia), eight sub-acute and specialised hospitals and
12 day case clinics (four of which operated by Intercare) across
South Africa, and around 8 600 inpatient beds; and Mediclinic
Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In
addition, under management contracts, Mediclinic Middle East
operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.
The Company's primary listing is on the London Stock Exchange
("LSE") in the United Kingdom, with secondary listings on the JSE
in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address : 6(th) Floor, 65 Gresham Street, London,
EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker : Morgan Stanley & Co International plc and
UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of
FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLUSOORASUNAAR
(END) Dow Jones Newswires
June 14, 2021 10:30 ET (14:30 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024